CXCL12 and prostate cancer: In terms of cancer metastasis, ROSI activates PPARγ and inhibits the activation of the PI3K-Akt pathway by inhibiting downregulation of CXCL12-induced migration and invasion on the CXCL12/CXCR4 axis in prostate cancer cell lines.